Protocol for pancreatic cancer

[Guest guest]

Revisiting the ALA/N (-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With

Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases

Burton M. Berkson, MD, MS, PhD

The Integrative Medical Center of New Mexico, Las Cruces, NM, USA, New Mexico

State University, Las Cruces, NM, USA

M. Rubin, ND, FABNO

Southwest College of Naturopathic Physicians, sdale, AZ, USA,

rubin@...

Arthur J. Berkson, MD

The Integrative Medical Center of New Mexico, Las Cruces, NM, USA

The authors, in a previous article, described the long-term survival of a man

with pancreatic cancer and metastases to the liver, treated with intravenous

alpha-lipoic acid and oral low-dose naltrexone (ALA/N) without any adverse

effects. He is alive and well 78 months after initial presentation. Three

additional pancreatic cancer case studies are presented in this article. At the

time of this writing, the first patient, GB, is alive and well 39 months after

presenting with adenocarcinoma of the pancreas with metastases to the liver. The

second patient, JK, who presented to the clinic with the same diagnosis was

treated with the ALA/N protocol and after 5 months of therapy, PET scan

demonstrated no evidence of disease. The third patient, RC, in addition to his

pancreatic cancer with liver and retroperitoneal metastases, has a history of

B-cell lymphoma and prostate adenocarcinoma. After 4 months of the ALA/N

protocol his PET scan demonstrated no signs of cancer. In this article, the

authors discuss the poly activity of ALA: as an agent that reduces oxidative

stress, its ability to stabilize NFkB, its ability to stimulate pro-oxidant

apoptosic activity, and its discriminative ability to discourage the

proliferation of malignant cells. In addition, the ability of lowdose naltrexone

to modulate an endogenous immune response is discussed. This is the second

article published on the ALA/N protocol and the authors believe the protocol

warrants clinical trial.

Key Words: pancreatic cancer • naltrexone • low-dose naltrexone • LDN • ALA/N •

-lipoic acid • NF B • nuclear factor B • antioxidant • gemcitabine

Integrative Cancer Therapies, Vol. 8, No. 4, 416-422 (2009)

DOI: 10.1177/1534735409352082